Loading…
NewAmsterdam Pharma Company N.V. is projected to rise to $49.33 by 2027, a +35% move from its current price of $36.56. NAMS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $35.39 | $36.56 | $37.77 | 0.00% |
| May 30 | $34.92 | $36.56 | $38.29 | +0.01% |
| May 31 | $34.56 | $36.57 | $38.69 | +0.01% |
| Jun 1 | $34.26 | $36.57 | $39.03 | +0.02% |
| Jun 2 | $34.00 | $36.57 | $39.33 | +0.02% |
| Jun 3 | $33.76 | $36.57 | $39.61 | +0.03% |
| Jun 4 | $33.55 | $36.57 | $39.87 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $33.55 | $36.57 | $39.87 | +0.03% |
| Week 2 | $32.38 | $36.58 | $41.33 | +0.07% |
| Week 3 | $31.52 | $36.60 | $42.49 | +0.10% |
| Week 4 | $30.81 | $36.61 | $43.50 | +0.13% |
| Week 5 | $30.20 | $36.62 | $44.41 | +0.17% |
| Week 6 | $29.66 | $36.63 | $45.25 | +0.20% |
| Week 7 | $29.17 | $36.65 | $46.04 | +0.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
NewAmsterdam Pharma Company N.V. (NAMS) currently trades at $35.44 and carries a market cap of $4.14B, with a rank of 1475. The current price sits alongside a 2026 forecast that lists a min of $28.43, an avg of $35.44, and a max of $46.56, with an ROI of 0 and sentiment NEUTRAL.
Looking further ahead, the forecast series shows ongoing bullish momentum, with higher avg prices and positive ROIs from 2027 through 2050 (e.g., 2027 avg $47.12, ROI 33; 2028 avg $59.70, ROI 68.4; 2029 avg $69.55, ROI 96.3; 2030 avg $71.80, ROI 102.6; 2031 avg $75.00, ROI 111.6; 2032 avg $87.90, ROI 148; 2033 avg $92.96, ROI 162.3; 2034 avg $116.18, ROI 227.8; 2035 avg $142.52, ROI 302.1; 2040 avg $208.74, ROI 489; 2050 avg $367.67, ROI 937.4). The technical backdrop supports a positive stance, with bullish sentiment overall, a 30-day range of $28.25–$44.45, a support level of $28.43, and a resistance at $39.59, while volatility runs at about 70% annualized.
A major floor 35.2% below — a decisive break under it would weaken the trend.
The nearest floor, 22.2% below — buyers have tended to step in here.
The nearest ceiling, 8.3% above — a clean break opens room to run.
A major ceiling 25.9% above — clearing it would confirm fresh momentum.
Key NAMS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAMS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.92 | Buy | $35.96 | Buy |
| MA 10 | $35.75 | Buy | $35.63 | Buy |
| MA 20 | $34.29 | Buy | $34.85 | Buy |
| MA 50 | $32.95 | Buy | $33.72 | Buy |
| MA 100 | $33.02 | Buy | $33.19 | Buy |
| MA 200 | $32.76 | Buy | $31.50 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.31 | Neutral |
| Stoch RSI (14) | 37.78 | Neutral |
| CCI (20) | 50.04 | Neutral |
| Williams %R (14) | -51.62 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -5.60 | Sell |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 48.38 | Neutral |
| TRIX (15) | 0.42 | Buy |
| Awesome (5,34) | 2.19 | Buy |
| Ultimate (7,14,28) | 61.42 | Neutral |
| Momentum (10) | -2.33 | Sell |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 36.24 | Buy |
| ADX (14) | 16.76 | Neutral |
| ATR (14) | 0.99 | Info |
The 30-day technical picture shows a bullish tilt, with RSI14 at 50 and the stock trading around key moving averages. The SMA50 is $32.67 and the SMA200 is $32.63, placing near-term support and resistance around $28.43 and $39.59, respectively. Over the last 30 days, the price has traded within a range of $28.25 to $44.45, highlighting room for both upside and pullbacks in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $28.43 | $36.56 | $48.32 | 0% | Neutral | |
| $38.39 | $49.33 | $67.57 | +35% | Bullish | |
| $46.73 | $62.07 | $88.61 | +70% | Bullish | |
| $53.81 | $73.49 | $108.40 | +101% | Bullish | |
| $54.62 | $76.48 | $115.95 | +109% | Bullish | |
| $55.69 | $79.77 | $123.87 | +118% | Bullish | |
| $64.87 | $94.93 | $150.62 | +160% | Bullish | |
| $67.95 | $101.46 | $164.15 | +178% | Bullish | |
| $82.29 | $125.25 | $206.29 | +243% | Bullish | |
| $99.25 | $153.90 | $257.71 | +321% | Bullish | |
| $135.35 | $228.49 | $410.04 | +525% | Bullish | |
| $210.66 | $413.37 | $819.99 | +10.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $28.43 | $36.56 | $43.10 | +0.00% |
| June 2026 | $30.79 | $36.31 | $43.95 | -0.69% |
| July 2026 | $30.82 | $36.72 | $45.16 | +1.14% |
| August 2026 | $31.77 | $38.14 | $47.49 | +3.88% |
| September 2026 | $31.14 | $37.64 | $47.33 | -1.33% |
| October 2026 | $29.69 | $36.10 | $45.81 | -4.07% |
| November 2026 | $29.92 | $36.57 | $46.77 | +1.30% |
| December 2026 | $30.53 | $37.51 | $48.32 | +2.55% |
Click any year to see its month-by-month NAMS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
NewAmsterdam Pharma Company N.V.'s 2026 outlook centres on $36.56, within a $28.43 to $48.32 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, NAMS could reach as high as $67.57, with a base case around $49.33 and support toward $38.39 — roughly +35% from $36.56. Buyers look set to stay in control over this stretch.
Expect NAMS to range from $46.73 to $88.61 through 2028. The $62.07 average target implies a +70% move from current prices. That is up +26% on the projected 2027 average. Momentum favours further upside here.
The NAMS price prediction for 2029 points to an average of $73.49 (low $53.81, high $108.40) — a potential gain of +101% on today's $36.56. Buyers look set to stay in control over this stretch.
In 2030, NAMS is projected to trade between $54.62 and $115.95, averaging $76.48 — a potential gain of +109% from today's $36.56. That is up +4% on the projected 2029 average. Momentum favours further upside here.
NewAmsterdam Pharma Company N.V.'s 2031 outlook centres on $79.77, within a $55.69 to $123.87 range. That is up +4% on the projected 2030 average. That marks a +118% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, NAMS could reach as high as $150.62, with a base case around $94.93 and support toward $64.87 — roughly +160% from $36.56. Momentum favours further upside here.
Expect NAMS to range from $67.95 to $164.15 through 2033. The $101.46 average target implies a +178% move from current prices. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The NAMS price prediction for 2034 points to an average of $125.25 (low $82.29, high $206.29) — a potential gain of +243% on today's $36.56. Momentum favours further upside here.
In 2035, NAMS is projected to trade between $99.25 and $257.71, averaging $153.90 — a potential gain of +321% from today's $36.56. That is up +23% on the projected 2034 average. Buyers look set to stay in control over this stretch.
NewAmsterdam Pharma Company N.V.'s 2040 outlook centres on $228.49, within a $135.35 to $410.04 range. That is up +48% on the projected 2035 average. That marks a +525% change versus current levels. Momentum favours further upside here.
By 2050, NAMS could reach as high as $819.99, with a base case around $413.37 and support toward $210.66 — roughly +10.3x from $36.56. Buyers look set to stay in control over this stretch.
Investing $1,000 in NAMS today (≈ 27.352298 NAMS) could be worth
$11,306.49
+$10,306.49 (+1031%) by 2050 · US Dollar
Based on the average projected NAMS price of $413.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAMSwould be worth at today's price.
$1,000 invested in NAMS on May 27, 2025 (≈ 58.788947 NAMS) would be worth
$2,149.32
+$1,149.32 (+114.9%) today · 2.15× · US Dollar
Based on a NAMS entry price of $17.01 vs. today's $36.56.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.75 | $1,022.66 | +2.3% |
| 1 month ago | $30.45 | $1,200.66 | +20.1% |
| 3 months ago | $34.28 | $1,066.51 | +6.7% |
| 6 months ago | $41.3 | $885.23 | -11.5% |
| 1 year ago | $17.01 | $2,149.32 | +114.9% |
| All time (5.0y) ago | $9.71 | $3,765.19 | +276.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAMS forecast.
Our base-case forecast reaches $73.00 around 2029.
Implied market cap at $73.00: $8.53B
The multi-year outlook points to substantial upside, with the average price rising from $35.44 in 2026 to $71.80 in 2030 and then higher across the decade and beyond. Notably, 2027 shows an avg of $47.12 (ROI 33%), 2028 $59.70 (ROI 68.4%), 2029 $69.55 (ROI 96.3%), 2030 $71.80 (ROI 102.6%), and 2031 $75.00 (ROI 111.6%). The trajectory continues to 2032 at $87.90 (ROI 148%), 2033 at $92.96 (ROI 162.3%), 2034 at $116.18 (ROI 227.8%), 2035 at $142.52 (ROI 302.1%), 2040 at $208.74 (ROI 489%), and 2050 at $367.67 (ROI 937.4%).
These are estimates, not guarantees, and depend on factors such as clinical outcomes and regulatory approvals. The drivers include Obicetrapib’s ongoing development as an oral CETP inhibitor for lowering LDL-C in cardiovascular diseases and its Phase 2a exploration for Alzheimer's disease, with a bullish tilt reflected in the long-horizon numbers.
Tap a question to reveal the answer.
The 2030 forecast lists an avg price of $71.80 with a min of $50.65 and a max of $110.29, and a ROI of 102.6% with bullish sentiment.
The forecast shows a neutral tone in 2026 (avg $35.44, ROI 0) and bullish momentum from 2027 onward, with rising averages and increasing ROIs through 2050.
Yes. The 2040 forecast shows an avg of $208.74 and a max of $381.93, with ROI at 489% and bullish sentiment.
Current price is $35.44 and market cap is $4.14B.
The 30-day range is $28.25–$44.45 with support at $28.43 and resistance at $39.59. RSI14 is 50, SMA50 is $32.67, SMA200 is $32.63, and annualized volatility is 70%.
NewAmsterdam Pharma Company N.V. Community Discussion
0Share your NewAmsterdam Pharma Company N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.